Director Dennis Langer resigns from Myriad Genetics, enters consulting agreement

MYRIAD GENETICS INC

Dennis Langer resigned as director effective June 30, 2022, not due to any disagreement with the company.
Myriad Genetics and Langer entered a one-year consulting agreement effective upon resignation.
Consulting agreement provides for hourly compensation and continued vesting of equity awards during term.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Dennis Langer

Director

MYGN · MYRIAD GENETICS INC

Effective: 2022-06-30
Filed: June 30, 2022, 7:59 PM ET

On June 28, 2022, Dennis Langer, a member of the Board of Directors of Myriad Genetics, Inc. (the “Company”), notified the Company that he is resigning as a director, effective June 30, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Dennis Langer resigned as Director at MYRIAD GENETICS INC.

Action: resigned
Role: Director

Exact text from the filing

On June 28, 2022, Dennis Langer, a member of the Board of Directors of Myriad Genetics, Inc. (the “Company”), notified the Company that he is resigning as a director, effective June 30, 2022.

View on SEC.gov

MYRIAD GENETICS INC filing history →

Source: SEC EDGAR

accession 0000899923-22-000096

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.